Amlodipine

Introduction Overview

Generic Name

amlodipine

Brand Name

Norvasc

Dosage Form

oral tablet (2.5 mg; 5 mg; 10 mg)

Drug Class

Calcium channel blockers

Pharmacokinetics

Absorption:
Amlodipine is well absorbed from the gastrointestinal tract after oral administration, with peak plasma concentrations generally achieved within 6 to 12 hours. Oral bioavailability is estimated to be between 64% and 90%, demonstrating relatively good systemic absorption. The drug exhibits a slow onset of action, which contributes to the gradual reduction in blood pressure. Food intake does not significantly affect the absorption of amlodipine, making it convenient for dosing without regard to meals.

Distribution:
Amlodipine has an extensive volume of distribution, approximately 21 L/kg, indicating wide distribution into body tissues. It is approximately 93% bound to plasma proteins, primarily albumin, which assists in sustained plasma levels. The drug readily crosses cell membranes to reach vascular smooth muscle tissues, specifically targeting calcium channels in these cells. The tissue binding properties contribute to amlodipine's long half-life and prolonged pharmacological effect.

Metabolism:
Amlodipine undergoes hepatic metabolism mainly through the cytochrome P450 system, particularly CYP3A4 isoenzyme. The drug is converted into inactive metabolites primarily via oxidative pathways. Hepatic metabolism is a crucial step, and thus, factors affecting liver enzyme activity can influence amlodipine clearance. Drug interactions with CYP3A4 inhibitors or inducers may alter plasma concentrations and therapeutic effects. Genetic polymorphisms in CYP enzymes can also modulate metabolism rates.

Elimination:
The elimination half-life of amlodipine is notably long, ranging from approximately 30 to 50 hours, allowing once-daily dosing. It is primarily excreted as inactive metabolites through the kidneys, with less than 10% of the parent drug found unchanged in the urine. The slow renal clearance contributes to steady plasma levels and sustained activity. In patients with impaired hepatic function, elimination may be prolonged, warranting careful dose adjustment and monitoring. The drug’s pharmacokinetics are generally not significantly affected by mild to moderate renal impairment.

Dosage Forms

Available Dosage Forms:
Norvasc is supplied as an oral tablet with three available strengths: 2.5 mg, 5 mg, and 10 mg. These film-coated tablets permit flexible dosing based on patient needs and tolerability.

Dosages for Adults and Adolescents:
For the treatment of hypertension, the usual starting dose in adults is 5 mg once daily, with a maintenance dose ranging from 5 to 10 mg once daily. In some cases, a lower starting dose of 2.5 mg may be utilized based on patient-specific factors. For angina pectoris and coronary artery disease, the maintenance dose is similarly 5 to 10 mg once daily. The maximum daily dose established for adults is 10 mg.

Specific Patient Populations:
In geriatric patients, the initial dose is generally reduced to 2.5 mg once daily to minimize risk of hypotension and other side effects, with a maintenance dosing range up to 10 mg daily based on clinical response. Pediatric dosing for hypertension in children aged 6 to 17 years typically starts with 2.5 mg once daily, not exceeding a maximum dose of 5 mg daily. Dose titration is conducted cautiously in patients with hepatic impairment due to prolonged elimination half-life. No dosage adjustment is usually necessary for patients with mild to moderate renal impairment, but careful monitoring is recommended.

Mechanism Of Action

Amlodipine is a dihydropyridine calcium channel blocker that selectively inhibits the influx of calcium ions through L-type calcium channels located primarily in vascular smooth muscle and cardiac muscle cells. By binding to these channels, amlodipine prevents calcium entry into the cells during depolarization, thereby inhibiting the contraction process.

This blockade results in vasodilation of peripheral arterial vessels, which reduces systemic vascular resistance and decreases arterial blood pressure. The reduction in afterload facilitates cardiac output by decreasing the workload on the heart. Additionally, amlodipine's vasodilatory effects increase coronary blood flow by dilating coronary arteries and arterioles, thereby alleviating myocardial ischemia associated with angina.

Unlike non-dihydropyridine calcium channel blockers that have pronounced effects on cardiac conduction and contractility, amlodipine primarily acts on vascular smooth muscle with minimal negative inotropic or chronotropic effects. This selective mechanism contributes to its favorable safety profile in patients with coronary artery disease or hypertension.

Clinical studies have demonstrated that long-term amlodipine therapy improves exercise tolerance and reduces frequency of anginal episodes. Its gradual onset and long half-life prevent sudden hypotensive episodes and minimize reflex tachycardia compared with other agents in the same class. Comparative research highlights that amlodipine’s sustained vasodilation improves patient compliance and cardiovascular outcomes in hypertensive and ischemic heart disease populations.

Pharmacological Actions

Calcium channel blockade resulting in relaxation of vascular smooth muscle.
Vasodilation of peripheral arteries leading to reduced systemic vascular resistance.
Increased coronary blood flow through coronary artery dilation.
Reduction of myocardial oxygen demand via decreased afterload.
Improvement of exercise tolerance in patients with angina pectoris.
Antihypertensive action by lowering elevated blood pressure.
Minimal negative effect on myocardial contractility and conduction.
Slow onset and long duration of action providing stable plasma drug levels.
Prevention of vasospasm associated with coronary artery disease.
Reduction of workload on the heart, beneficial in heart failure patients with hypertension.

Therapeutic Or Clinical Uses

Management of hypertension in adults and children aged 6 years and older.
Treatment of angina pectoris including chronic stable angina and vasospastic angina (Prinzmetal’s angina).
Reduction of morbidity associated with coronary artery disease by improving myocardial oxygen supply.
Adjunct therapy in the treatment of congestive heart failure with concomitant hypertension (used cautiously).
Prevention of stroke, myocardial infarction, and renal complications by effective blood pressure control.
Control of high blood pressure in elderly patients with tailored dosing.
Off-label use in pediatric hypertension management under specialist supervision.
Combination therapy with other antihypertensive agents for enhanced blood pressure control.
Reduction of blood pressure variability to minimize cardiovascular risks.

Side Or Adverse Effects

Peripheral edema, particularly swelling of the legs and ankles, occurring in approximately 5-9% of patients.
Dizziness and light-headedness, especially upon standing (orthostatic hypotension).
Flushing characterized by sudden warmth, redness, or tingling sensations.
Palpitations or pounding heartbeats due to vascular effects.
Fatigue and drowsiness reported by some patients.
Nausea and abdominal discomfort in rare instances.
Muscle cramps or stiffness and in some cases uncontrolled muscle movements.
Rare allergic reactions including rash, hives, or swelling of the face and throat.
Infrequent worsening of angina or myocardial ischemia upon initiation or dosage increase.
Headache and sensations of warmth due to vasodilation.
Rapid heartbeat or irregular heartbeat (arrhythmia) in susceptible individuals.
Gastrointestinal disturbances such as abdominal pain.
Potential dizziness leading to falls in elderly patients.
Rarely, gum hypertrophy and fatigue.
Edema induced weight gain, more prevalent with higher doses and in women.

Precautions

Use caution in patients with congestive heart failure or severe aortic stenosis due to potential hemodynamic effects.
Patients with hepatic impairment require dose adjustments because of reduced drug clearance.
Monitor blood pressure regularly to avoid hypotension, especially during dose titration.
Advise patients to avoid rapid position changes to minimize dizziness and risk of falls.
Caution when prescribing to pregnant women; benefits should outweigh risks as safety is not fully established.
Breastfeeding patients should consult healthcare providers before using amlodipine.
Careful monitoring is necessary in elderly patients due to increased sensitivity and risk of adverse effects.
Avoid concomitant use with strong CYP3A4 inhibitors or inducers unless closely monitored.
Regular follow-up required to monitor for worsening angina symptoms upon treatment initiation.
Advise patients not to abruptly discontinue the medication to prevent rebound hypertension.
Alcohol consumption should be minimized as it may exacerbate hypotensive effects.
Use with caution in patients with coronary artery disease to avoid paradoxical worsening of angina.
Inform patients about the possibility of peripheral edema and instruct them to report unexplained swelling.
Be vigilant for signs of allergic reactions and instruct patients to seek immediate care if they occur.
Assess renal function periodically despite limited renal elimination.

Warnings

Potential worsening of chest pain or occurrence of myocardial infarction when therapy is started or dose increased.
Patients with congestive heart failure and impaired left ventricular function should be monitored due to fluid retention risks.
Severe hypotension may develop in sensitive patients or when combined with other antihypertensives.
Use caution in patients with liver disease due to reduced metabolism and clearance of amlodipine.
Excessive hypotension may cause dizziness, fainting, or falls particularly in elderly patients.
Alcohol consumption can potentiate blood pressure lowering effects and increase side effects.
Not established as safe in pregnancy; monitor mother and fetus carefully if used during this period.
Rapid discontinuation may cause rebound hypertension; tapering off is recommended under medical supervision.
Patients should be informed of signs of allergic reactions, which require emergency attention.
Monitor for peripheral edema, which may necessitate dose modification or therapy change.
Concomitant use with other medications affecting blood pressure may require dose adjustments.
Careful monitoring required in patients with severe aortic stenosis due to hemodynamic effects.
Avoid abrupt cessation especially in angina patients to prevent rebound symptoms.
Use caution in patients at risk for hypotension secondary to volume depletion or dehydration.
Chest pain worsening requires immediate medical evaluation.

Contraindication

Known hypersensitivity or allergy to amlodipine or any components of the formulation.
Severe hypotension or cardiogenic shock states where vasodilation could exacerbate condition.
Use in patients with unstable angina or recent myocardial infarction without specialist supervision.
Severe aortic stenosis where vasodilation may critically reduce coronary perfusion pressure.
Patients with obstructive cardiomyopathies where afterload reduction may be detrimental.
Hypersensitivity reactions to dihydropyridine calcium channel blockers.
Concomitant use with drugs contraindicated due to interactions leading to excessive hypotension.
Patients with a history of angioedema related to amlodipine should avoid use.
Should not be used as first-line monotherapy in patients with significant heart failure without specialist advice.
Known intolerance due to prior serious adverse reactions to the drug.
Active liver disease with severely compromised metabolism.
Pediatric patients under 6 years of age due to lack of safety data.
Severe hypotension or cardiogenic shock.
Pregnancy category caution under specialist supervision; avoid if safer alternatives are available.
Significant drug interactions contraindicated in patient medication profile.

Drug Interactions

CYP3A4 inhibitors such as ketoconazole, itraconazole, and ritonavir can increase amlodipine plasma levels, raising risk of hypotension and adverse effects.
CYP3A4 inducers like rifampin and carbamazepine may reduce amlodipine efficacy by increasing metabolism.
Concomitant use with other antihypertensives may cause additive hypotensive effects requiring dose adjustments.
Use with beta-blockers may enhance antihypertensive and antianginal effects but requires monitoring for bradycardia or hypotension.
Caution with simvastatin as amlodipine can increase its plasma concentration, raising risk of statin-related side effects.
Use with alcohol can potentiate blood pressure lowering and increase dizziness and risk of falls.
Concomitant use with grapefruit juice may increase amlodipine plasma levels via CYP3A4 inhibition.
Use with lithium may increase lithium toxicity due to decreased renal clearance influenced by blood pressure changes.
Risks increase when combined with other calcium channel blockers, potentially causing excessive hypotension or cardiac depression.
Use with diuretics may enhance hypotensive effects and risk of electrolyte imbalance.
Co-administration with NSAIDs may reduce antihypertensive efficacy.
Interactions with CYP3A4 substrates or inhibitors necessitate close monitoring and possible dose modification.
Concurrent use with digoxin requires monitoring as hemodynamic changes may alter digoxin levels or effects.
Careful monitoring is necessary if combined with antiarrhythmic agents due to potential additive cardiac effects.
Vitamin supplements and herbal products should be disclosed as some may alter CYP3A4 activity.

Preparations Of The Drug

Norvasc oral tablets are available in 2.5 mg, 5 mg, and 10 mg strengths.
Film-coated tablets designed for once-daily oral administration.
Available under several brand names including Katerzia and Norliqva (oral suspension forms).
Formulated with inactive ingredients: microcrystalline cellulose, dibasic calcium phosphate anhydrous, sodium starch glycolate, and magnesium stearate.
Packaging options include blister packs and bottles to maintain tablet integrity.
Storage recommended at room temperature, protected from moisture, heat, and light.
Generic formulations of amlodipine besylate available to reduce therapy costs.
Pharmaceutical grade with consistent bioavailability across brands.
Oral suspension forms available under alternative brands for pediatric patients unable to swallow tablets.
Non-oral forms are not commercially available; use limited to oral administration.
Manufactured primarily by Pfizer Inc., complying with regulatory standards.
Available with or without lactose to accommodate patient tolerability.
Prescribed exclusively by authorized healthcare providers with appropriate labeling and patient guidance.
Combination formulations with other antihypertensive drugs are commercially available but distinct from Norvasc monotherapy.
Shelf-life and expiration dates strictly maintained to ensure potency.